Previous 10 | Next 10 |
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...
CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...
CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syst...
CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...
2024-02-02 16:43:29 ET More on Reviva Pharmaceuticals AbbVie – Cerevel M&A deal lifts Reviva, Karuna Reviva Pharma slips on $30M stock offering Read the full article on Seeking Alpha For further details see: Reviva Pharmaceuticals files for $20...
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and ca...
2024-01-23 07:32:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,”...
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardio...
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supporting a differentiated profile for once-daily brilaroxazine – – I...
2023-12-22 12:23:57 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Polished.com Inc...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label ext...
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial expected to initiate Q2 2024; topline data expected Q3 2025 – ...
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...